• Skip to primary navigation
  • Skip to main content
ASC Therapeutics

ASC Therapeutics

Genes and Cells for Cure

  • About Us
    • Our Team
    • Hemophilia Advisory Board
    • Cell Therapy Advisory Board
  • Our Technology
  • Focus
    • Gene Therapy
    • Stem Cell Therapy
  • Our Pipeline
  • Our Partners
  • Investors
    • Investors
    • Releases
  • News
    • Publications
    • Industry News
    • Company News

Press Release

ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing

January 14, 2020 By admin

MILPITAS, Calif.--(BUSINESS WIRE)--ASC Therapeutics (“ASC”), a privately-held gene therapy company focused on developing transformative gene-based medicines for serious diseases, announced today that it has entered into a long-term strategic manufacturing partnership with Vigene Biosciences

ASC Therapeutics Licenses Tech from Expression Therapeutics to Advance Gene Therapies

May 16, 2019 By admin

5/16/19 MILPITAS, Calif.–(BUSINESS WIRE) — ASC Therapeutics, A Division of Applied StemCell, Inc. (ASC), announced today that it has obtained an exclusive therapeutics license from Expression Therapeutics, LLC (ET) for coagulation factor VIII expression technologies including a highly compact, yet

ASC Therapeutics Cures Hemophilia A Mice

April 25, 2019 By admin

4/25/19 MILPITAS, Calif.–(BUSINESS WIRE)– Applied StemCell, Inc. (ASC), a leading gene-editing company, announced that its therapeutic division (ASC Therapeutics) has cured Hemophilia A in mice and will be presenting their in vivo and in vitro findings at the 22nd Annual Meeting of The American

Copyright © 2021 ASC Therapeutics

This website uses cookies to improve your experience. We'll assume you accept this policy as long as you are using this websiteAcceptLearn More